By Gilang Cahya 
Scientists at the Francis Crick Institute and Vividion Therapeutics have achieved a significant milestone in cancer research with the discovery of novel chemical compounds designed to precisely inhibit the cancer-driving RAS gene from interacting with a crucial pathway that fuels tumor growth. This groundbreaking development, which has the potential to revolutionize cancer treatment by offering a targeted approach with fewer side effects, has now advanced into its first human clinical trial. The successful progression of this research into human testing marks a pivotal moment in the long-standing effort to effectively combat cancers driven by RAS mutations, which are estimated to occur in approximately 20% of all human malignancies.
The Ubiquitous RAS Gene and the Challenge of Targeted Therapy
The RAS gene family, comprising KRAS, HRAS, and NRAS, plays a fundamental role in cellular communication, acting as a molecular switch that regulates cell growth, division, and differentiation. In healthy cells, these signals are tightly controlled, ensuring orderly development and tissue maintenance. However, mutations within the RAS genes can render this switch permanently "on," leading to uncontrolled cell proliferation – a hallmark of cancer. The prevalence of RAS mutations across a wide spectrum of cancers, including pancreatic, lung, colorectal, and melanoma, underscores their significance as a major driver of oncogenesis.
For decades, the RAS gene has been considered "undruggable" due to its intricate role in essential cellular processes. Directly inhibiting RAS itself or the downstream enzymes it activates has proven exceptionally challenging. The very pathways that RAS hijacks for cancer growth are also vital for normal cellular functions, including immune responses, metabolic regulation, and tissue repair. Consequently, therapies that broadly suppress these pathways often result in debilitating side effects, severely limiting their therapeutic utility and patient tolerance.
One such critical pathway is regulated by phosphoinositide 3-kinase (PI3K). PI3K is a central player in cell growth and survival, and its aberrant activation by mutated RAS is a common driver of tumor progression. However, PI3K also plays a critical role in insulin signaling, which is essential for glucose metabolism and maintaining blood sugar levels. Inhibiting PI3K too broadly can lead to severe metabolic disturbances, most notably hyperglycemia, a condition that can have serious health consequences. This delicate balance has historically prevented the development of effective and safe treatments targeting the RAS-PI3K axis.
A Novel Approach: Precision Disruption of Protein-Protein Interaction
The recent breakthrough, detailed in a study published on October 9th in the prestigious journal Science, represents a paradigm shift in targeting the RAS pathway. Instead of attempting to broadly inhibit RAS or PI3K, the research teams at the Francis Crick Institute and Vividion Therapeutics focused on a more precise strategy: preventing the physical interaction between RAS and PI3K.
This innovative approach leverages the power of chemical biology and advanced screening techniques. Vividion Therapeutics, a company specializing in the discovery of novel small molecules that modulate protein function, utilized its proprietary platform to screen vast libraries of chemical compounds. The goal was to identify molecules that could specifically bind to PI3K at the very site where RAS would normally dock. By occupying this critical interaction interface, these compounds could effectively block the signal from RAS to PI3K, thereby halting the downstream cascade of events that promotes cancer cell growth, without indiscriminately shutting down PI3K’s other essential functions.
The Crick researchers, led by Julian Downward, a renowned expert in oncogene biology, developed sophisticated biological assays to rigorously test the efficacy and specificity of these identified compounds. These assays allowed them to confirm that the molecules from Vividion could indeed prevent the RAS-PI3K interaction. Crucially, the testing also demonstrated that these compounds did not interfere with PI3K’s ability to engage with other binding partners and carry out its normal physiological roles, particularly those related to insulin signaling. This selectivity is the key to minimizing off-target effects and potential side effects.
Promising Preclinical Results Pave the Way for Clinical Trials
The preclinical studies conducted by the research teams provided compelling evidence of the therapeutic potential of these novel compounds. In experiments involving mice bearing lung tumors with RAS mutations, a selected compound effectively halted tumor growth. This was a significant achievement, as it demonstrated the ability of the drug to target a key oncogenic driver without inducing adverse metabolic consequences, such as elevated blood sugar levels, which have plagued previous attempts to inhibit the RAS pathway.
Further enhancing the promise of this new therapeutic strategy, the researchers explored combining the novel compound with other existing or experimental cancer drugs. In these synergistic studies, the co-administration of the PI3K-RAS interaction inhibitor with one or two additional agents targeting different components of the same signaling pathway led to significantly more potent and sustained tumor suppression than any of the drugs used individually. This suggests that the compounds could be a valuable component of combination therapies, offering a more comprehensive and durable attack against cancer.
The versatility of this approach was further underscored by its effectiveness in models of other cancers. When tested in mice with HER2-mutated tumors, which are often seen in breast cancer and also rely on PI3K for growth, the compound demonstrated significant tumor inhibition. This finding was particularly noteworthy because, in these HER2-driven cancers, the benefit was observed even when RAS was not the primary oncogenic driver. This suggests that the compound’s ability to modulate PI3K signaling could extend its utility to a broader spectrum of cancers beyond those directly driven by RAS mutations.
Entering the Clinic: A New Era of Hope
The robust preclinical data has propelled this innovative research into the crucial next phase: human clinical trials. The first-in-human trial, now underway, will systematically evaluate the safety and tolerability of the compound in patients with both RAS and HER2 mutations. Beyond assessing safety, the trial will also investigate the efficacy of the drug, particularly when administered in combination with other therapies known to target the RAS pathway. This multi-pronged approach in the clinical setting is designed to rapidly identify the optimal therapeutic strategies for patients.
Julian Downward, Principal Group Leader of the Oncogene Biology Laboratory at the Crick, expressed his enthusiasm about the commencement of clinical trials. "Given the RAS gene is mutated across a wide range of cancers, we’ve been exploring how to stop it interacting with cell growth pathways for many years, but side effects have held back the development of treatments," he stated. "Our collaborative effort has overcome this challenge by targeting the PI3K and RAS interaction specifically, leaving PI3K free to bind with its other targets. It’s exciting to see these clinical trials starting, highlighting the power of understanding chemistry and fundamental biology to get to something with potential to help people with cancer."
Matt Patricelli, Ph.D., Chief Scientific Officer of Vividion Therapeutics, echoed this sentiment, emphasizing the novel discovery approach. "This discovery is a great example of how new discovery approaches can open up completely novel ways to tackle cancer," he remarked. "By designing molecules that stop RAS and PI3K from connecting, while still allowing healthy cell processes to continue, we’ve found a way to selectively block a key cancer growth signal. It’s incredibly rewarding to see this science now progressing in the clinic, where it has the potential to make a real difference for patients."
Broader Implications for Cancer Treatment
The successful translation of this research from the laboratory bench to the patient bedside holds profound implications for the future of cancer therapy. The ability to precisely target a critical oncogenic pathway without causing widespread disruption to normal cellular functions could usher in an era of highly personalized and less toxic cancer treatments.
For patients with RAS-mutated cancers, who have historically faced limited and often harsh treatment options, this development offers a renewed sense of hope. The prospect of a therapy that can effectively control tumor growth while preserving quality of life is a significant advancement. Furthermore, the demonstrated efficacy in HER2-mutated cancers suggests a wider applicability, potentially benefiting a larger patient population.
The success of this collaborative effort between academic research and the pharmaceutical industry also highlights the critical importance of interdisciplinary approaches in tackling complex diseases like cancer. The integration of deep biological understanding from the Crick Institute with Vividion Therapeutics’ expertise in chemical synthesis and drug discovery has been instrumental in overcoming long-standing challenges.
As the clinical trials progress, the scientific and medical communities will be closely watching for further evidence of the safety and efficacy of these compounds. If proven successful, this new class of targeted therapies could fundamentally alter the treatment landscape for numerous cancers, offering a more precise, effective, and tolerable approach to combating this devastating disease. The journey from identifying a critical molecular interaction to developing a clinically viable drug is arduous and complex, but this latest development marks a significant stride forward, demonstrating the relentless pursuit of innovation in the fight against cancer.
